Edwards Lifesciences (EW) Stock Forecast & Price Target

$87.59 +1.74 (+2.03%)

Closing price 06/9/2026 03:59 PM Eastern

Extended Trading

$86.75 -0.84 (-0.96%)

As of 04:04 AM Eastern

Compare

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
8

Buy
19

Based on 27 Wall Street analysts who have issued ratings for Edwards Lifesciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 8 have given a hold rating, 16 have given a buy rating, and 3 have given a strong buy rating for EW.

Consensus Price Target

$95.96
9.55% Upside

According to the 27 analysts' twelve-month price targets for Edwards Lifesciences, the average price target is $95.96. The highest price target for EW is $110.00, while the lowest price target for EW is $81.00. The average price target represents a forecasted upside of 9.55% from the current price of $87.59.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for EW and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Edwards Lifesciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EW Analyst Ratings Over Time

Type	Current Forecast 6/10/25 to 6/10/26	1 Month Ago 5/11/25 to 5/11/26	3 Months Ago 3/12/25 to 3/12/26	1 Year Ago 6/10/24 to 6/10/25
Strong Buy	3 Strong Buy rating(s)	3 Strong Buy rating(s)	3 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	15 Buy rating(s)	10 Buy rating(s)
Hold	8 Hold rating(s)	9 Hold rating(s)	9 Hold rating(s)	12 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$95.96	$95.65	$96.14	$80.20
Forecasted Upside	9.55% Upside	24.04% Upside	13.61% Upside	5.87% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

EW Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EW Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Edwards Lifesciences Stock vs. The Competition

Type	Edwards Lifesciences	Medical Companies	Broader Market
Consensus Rating Score	2.81	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	9.55% Upside	760.77% Upside	14.83% Upside
News Sentiment Rating	Positive News See Recent EW News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
6/2/2026	TD Cowen 3 of 5 stars	Joshua Jennings Not Rated	Reiterated Rating	Buy	$97.00 ➝ $104.00	+20.47%
4/27/2026	Barclays 3 of 5 stars	Matt Miksic 2 of 5 stars	Reiterated Rating	Overweight	$104.00 ➝ $110.00	+30.64%
4/24/2026	Truist Financial 3 of 5 stars	Richard Newitter 2 of 5 stars	Set Target	Hold	$89.00 ➝ $90.00	+8.03%
4/24/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform	$93.00	+11.71%
4/24/2026	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Plovanic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold	$87.00 ➝ $85.00	+2.10%
4/24/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$85.00 ➝ $87.00	+9.17%
4/24/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Marie Thibault Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$98.00 ➝ $100.00	+25.48%
4/20/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold (C)
4/13/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$100.00 ➝ $95.00	+22.95%
4/1/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$92.00	+14.91%
SpaceX is offering you shares. Don't take them. (Ad) SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required. Get the backdoor ticker free before the SpaceX IPO launches
2/11/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$108.00 ➝ $95.00	+23.38%
2/11/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight	$98.00 ➝ $100.00	+29.87%
2/11/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$96.00 ➝ $100.00	+31.67%
2/4/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Antalffy Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$94.00	+14.94%
1/20/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$105.00 ➝ $110.00	+30.35%
12/18/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robbie Marcus Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$90.00 ➝ $100.00	+17.85%
12/11/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$96.00 ➝ $101.00	+20.29%
12/5/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$95.00 ➝ $100.00	+15.60%
11/3/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform	$90.00	+9.12%
11/3/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jayson Bedford Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$96.00	+16.39%
10/31/2025	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Target		$92.00	+11.54%
10/29/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Hold ➝ Buy	$80.00 ➝ $98.00	+19.14%
10/8/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Suraj Kalia Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
7/29/2025	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Strong-Buy
7/25/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Strong-Buy
7/25/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Pito Chickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$85.00 ➝ $94.00	+24.21%
7/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Wood Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$75.00 ➝ $81.00	+3.39%
7/10/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christine Dooley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
6/2/2025	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	N. Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Hold
12/16/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$82.00 ➝ $90.00	+20.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:37 AM ET.

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, June 7, 2026. Please send any questions or comments about these Edwards Lifesciences pros and cons to contact@marketbeat.com.

Edwards Lifesciences
Bull Case

Here are some ways that investors could benefit from investing in Edwards Lifesciences Co.:

The current stock price is around $81, which reflects a stable position within its 12-month range, indicating potential for growth.
Edwards Lifesciences Co. reported a significant revenue increase of 16.7% compared to the same quarter last year, showcasing strong demand for its products.
The company has a low debt-to-equity ratio of 0.06, suggesting a strong balance sheet and lower financial risk, which is attractive for investors seeking stability.
With a return on equity of 15.19%, Edwards Lifesciences Co. demonstrates effective management and profitability, indicating good potential for shareholder returns.
The firm has set ambitious earnings guidance for FY 2026, projecting EPS between 2.950 and 3.050, which could signal future growth and profitability.

Edwards Lifesciences
Bear Case

Investors should be bearish about investing in Edwards Lifesciences Co. for these reasons:

The price-to-earnings (P/E) ratio is relatively high at around 45.71, which may indicate that the stock is overvalued compared to its earnings.
Despite recent revenue growth, the company operates in a competitive medical technology market, which could impact future sales and market share.
The beta of 0.87 suggests that the stock is less volatile than the market, which may limit potential high returns during bullish market conditions.
Analysts predict that the company will post only 3 earnings per share for the current year, which may not meet investor expectations for growth.
Market capitalization fluctuations, currently around $49.48 billion, could affect investor confidence and stock performance in the long term.

EW Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Edwards Lifesciences is $95.96, with a high forecast of $110.00 and a low forecast of $81.00.

27 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last twelve months. There are currently 8 hold ratings, 16 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EW shares.

According to analysts, Edwards Lifesciences's stock has a predicted upside of 9.55% based on their 12-month stock forecasts.

Over the previous 90 days, Edwards Lifesciences's stock had 1 upgrade by analysts.

Edwards Lifesciences has been rated by research analysts at Barclays, BTIG Research, Canaccord Genuity Group, Evercore, Mizuho, Robert W. Baird, TD Cowen, Truist Financial, Weiss Ratings, and Wolfe Research in the past 90 days.

Analysts like Edwards Lifesciences more than other "medical" companies. The consensus rating for Edwards Lifesciences is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how EW compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

This page (NYSE:EW) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case

EW Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

EW Analyst Ratings Over Time

EW Analyst Recommendations By Month

EW Price Targets by Month

Edwards Lifesciences Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Edwards Lifesciences Stock? EW Pros and Cons Explained

Edwards Lifesciences Bull Case

Edwards Lifesciences Bear Case

EW Forecast - Frequently Asked Questions

What is Edwards Lifesciences' forecast for 2026?

Should I buy or sell Edwards Lifesciences stock right now?

Does Edwards Lifesciences's stock price have much upside?

Has Edwards Lifesciences been upgraded by Wall Street analysts recently?

What analysts cover Edwards Lifesciences?

Do Wall Street analysts like Edwards Lifesciences more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Edwards Lifesciences Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Edwards Lifesciences
Bull Case

Edwards Lifesciences
Bear Case